Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 5Recurrence 3Lymphoma 3Glioblastoma 3Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Glioma 2Brain Neoplasms 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Leukemia 1Gliosarcoma 1Ependymoma 1Disease Progression 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 25Magnetic Resonance Spectroscopy 19Etoposide 14Cyclophosphamide 13Radiotherapy 10Filgrastim 10Bevacizumab 10Carboplatin 9Biopsy 8Cisplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Carmustine 6Radiation 5Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Erlotinib Hydrochloride 4Azacitidine 4olaparib 3etoposide phosphate 3Surgical Procedures, Operative 3Lapatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ependymoma × marizomib × Clear all
NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡